Literature DB >> 11562620

Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies.

S C Reinalter1, H J Gröne, M Konrad, H W Seyberth, G Klaus.   

Abstract

OBJECTIVE: Evaluation of the benefit/risk ratio of long-term treatment with indomethacin in salt-losing tubulopathies with special attention to renal function. STUDY
DESIGN: Twelve patients (median age, 14.9 years) had received indomethacin for a median of 13 years (median cumulative dose, 10.7 g/kg). Creatinine clearance, serum electrolyte levels, endocrine status, and excretion of prostaglandins and electrolytes were examined during indomethacin therapy and after its withdrawal. All patients underwent ultrasound-guided renal biopsy. For statistical evaluation, the Wilcoxon test and Pearson correlation coefficient were used.
RESULTS: After indomethacin withdrawal, the biochemical features of the tubulopathy reappeared. The median creatinine clearance rose from 67.4 to 96.5 mL/min/1.73 m(2) (P <.05) but remained subnormal in 4 patients. Ultrasonography elucidated medullary nephrocalcinosis in 8 patients. Renal tissue showed slight/moderate focal tubular atrophy and interstitial fibrosis in 8 patients. Comparison with biopsy specimens, obtained 11 to 14 years before study participation from 5 patients, revealed no progression. A correlation between fractional sodium and magnesium excretion and percentage of altered tubulointerstitial compartment was found (P <.001). The 4 patients with mutations in the gene of the inwardly rectifying adenosine triphosphate-regulated potassium channel (ROMK) had almost normal renal histologic findings and normal renal function.
CONCLUSION: Renal function and histology are unaffected by long-term indomethacin treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562620     DOI: 10.1067/mpd.2001.117007

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Chronic renal failure in a boy with classic Bartter's syndrome due to a novel mutation in CLCNKB coding for the chloride channel.

Authors:  Chien-Ming Lin; Jeng-Daw Tsai; Yi-Fen Lo; Ming-Tso Yan; Sung-Sen Yang; Shih-Hua Lin
Journal:  Eur J Pediatr       Date:  2008-12-03       Impact factor: 3.183

Review 2.  Pathophysiology and clinical presentations of salt-losing tubulopathies.

Authors:  Hannsjörg W Seyberth
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

3.  Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome.

Authors:  Gaël Gasongo; Larry A Greenbaum; Olivier Niel; Theresa Kwon; Marie-Alice Macher; Anne Maisin; Véronique Baudouin; Claire Dossier; Georges Deschênes; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2018-11-13       Impact factor: 3.714

4.  Type IV Bartter syndrome: report of two new cases.

Authors:  Marco Zaffanello; Anna Taranta; Alessia Palma; Alberto Bettinelli; Gian Luigi Marseglia; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2006-04-01       Impact factor: 3.714

Review 5.  Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Authors:  Hannsjörg W Seyberth; Karl P Schlingmann
Journal:  Pediatr Nephrol       Date:  2011-04-19       Impact factor: 3.714

6.  Primary molecular disorders and secondary biological adaptations in bartter syndrome.

Authors:  Georges Deschênes; Marc Fila
Journal:  Int J Nephrol       Date:  2011-09-20

7.  Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome.

Authors:  Thomas R Welch; David R Shaffer; Darren R Feldman
Journal:  Case Rep Nephrol Dial       Date:  2017-05-08

8.  Clinical and diagnostic features of Bartter and Gitelman syndromes.

Authors:  Patrick R Walsh; Yincent Tse; Emma Ashton; Daniela Iancu; Lucy Jenkins; Marc Bienias; Robert Kleta; William Van't Hoff; Detlef Bockenhauer
Journal:  Clin Kidney J       Date:  2017-11-10

9.  A Chinese Girl with Bartter Syndrome Type III due to a Novel Mutation and/or Single Nucleotide Polymorphisms (SNPs) in CLCNKB Gene.

Authors:  Wang Xiumin; Shen Zheng; Xu Meichun; Fu Junfen; Liang Li
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.